FMI has projected the anti-osteoporosis therapy and fracture healing-market to record a CAGR of 3% through 2030. The demand for anti-osteoporosis therapy and fracture healing treatment is anticipated to continue surging due to the rising demand for non-invasive therapeutics.
Osteoporosis is a chronic and a life-threatening disease in which the microstructure of bones is altered due to reduction in bone mass and bone density. This condition leads to increased bone brittleness and risk of bone fractures and cracks. Thus, osteoporosis is considered life threatening due to severe injury and associated pain. The significant reduction in the bone mass density leads to changes in microstructure of the bones resulting in increased threat of bone cracks and bone fractures.
According to the International Osteoporosis Foundation (IOF), osteoporosis is also known as a silent disease because many people do not know they have osteoporosis until they have a fist fracture. Based on an IOF report, each year osteoporosis causes more than 8.9 million fractures and bone cracks across the globe. Furthermore, it is indicated that nearly 200 million women all over the world are being affected by osteoporosis every year.
For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-1008
“Key players are adopting merger and acquisition strategies for increasing their presence across the globe,” says the FMI analyst.
Anti-Osteoporosis Therapy And Fracture Healing treatment Market – Important Highlights
- Bisphosphonates will remain the preferred drug type due to the growing adaptation to target-specific treatments
- The oral route of administration is expected to remain most preferred
- Profit from hospital pharmacy is projected to grow by 2X by 2030 compared to 2019.
- The U.S. is leading the global market for anti-osteoporosis treatment and fracture healing, with revenues estimated to exceed US$ 6.3 billion by 2030
Anti-Osteoporosis Therapy And Fracture Healing Treatment Market – Drivers
- Increase in geriatric population, who are at high risk of osteoporosis, is driving the market
- The increasing pace of drug approval and commercialization are enabling growth
- Increasing investment in innovation and new product launches are expected to boost the market
Anti-Osteoporosis Therapy and Fracture Healing Treatment Market – Restraints
- Significantly less understanding of osteoporosis and its treatment choices in GCC countries is hindering the growth of the market.
- Poor economic conditions and healthcare infrastructure might hinder the adoption of anti-osteoporosis therapy and fracture healing treatment across some countries
COVID-19 Impact on Anti-Osteoporosis Therapy And Fracture Healing treatment Market
During this time there has been a disruption in the supply and demand chain which has caused an impact on the revenue of the Anti-Osteoporosis Therapy And Fracture Healing treatment in a negative way. However, this is estimated to be a temporary effect and the market is expected to have a turnaround.
The pandemic has led to a decrease in the patient’s flow in the hospitals, and doctor chambers. This has caused a reduction in the number of surgeries and that in turn has affected the Anti-Osteoporosis Therapy And Fracture Healing treatment market.
For Information On The Research Approach Used In The Report, Ask Analyst @ https://www.futuremarketinsights.com/askus/rep-gb-1008
Competitive Landscape
Key companies are aiming at strategic collaboration. The Anti-osteoporosis treatment and fracture healing industry is a relatively consolidated market with fewer than 10 market players comprising more than 50% of the overall revenue.
Some of the leading companies operating in the market are Eli Lilly and Company, Pfizer Inc., Amgen Inc., Merck and Company, Inc., Novartis International AG, F. Hoffmann La Roche Ltd.
About the Study
The study offers readers a comprehensive assessment of the Anti-Osteoporosis Therapy And Fracture Healing treatment market. Global, regional, and national-level analysis of the latest trends influencing the market is covered in this FMI report. The study provides insights based on drug class (Bisphosphonates, Calcitonin, Estrogen or Hormone Replacement Therapy), route of administration (oral, injectable), distribution channel (Hospital Pharmacies, Retail Pharmacies, Online sales), and across key regions (North America, Latin America, Europe, China, Asia Pacific, Middle East & Africa).
For Read More Related Insights:
https://network-759413.mn.co/posts/24828675?utm_source=manual
https://cipmo-system.mn.co/posts/24828676?utm_source=manual
https://domain.tribe.so/post/varicose-vein-treatment-market-trends-size-growth-insight-share-competitive–62c289996b550d2cab03f4d9
https://drujrake.mn.co/posts/24828678?utm_source=manual
About FMI:
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Unit No: 1602-006
Jumeirah Bay 2
Plot No: JLT-PH2-X2A
Jumeirah Lakes Towers
Dubai
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs